Multimodal Percutaneous Thermal Ablation of Small Hepatocellular Carcinoma: Predictive Factors of Recurrence and Survival in Western Patients.
hepatocellular carcinoma
liver
microwave ablation
percutaneous thermal ablation
radiofrequency ablation
recurrence
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jan 2020
29 Jan 2020
Historique:
received:
27
12
2019
revised:
15
01
2020
accepted:
26
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
To identify the predictive factors of recurrence and survival in an unselected population of Western patients who underwent multimodal percutaneous thermal ablation (PTA) for small Hepatocellular Carcinomas (HCCs). January 2015-June 2019: data on multimodal PTA for <3 cm HCC were extracted from a prospective database. Local tumor progression (LTP), intrahepatic distant recurrence (IDR), time-to-LTP, time-to-IDR, recurrence-free (RFS) and overall (OS) survival were evaluated. 238 patients underwent 317 PTA sessions to treat 412 HCCs. During follow-up (median: 27.1 months), 47.1% patients had IDR and 18.5% died. LTP occurred after 13.3% of PTA. Tumor size (OR = 1.108, IDR was associated with tumor aggressiveness, suggesting a metastatic mechanism. Besides AFP association with LTP, IDR, RFS and OS, treatment-naïve patients had longer RFS, and multi-nodularity was associated with shorter RFS and OS. Steatotic HCC, identified on pre-treatment MRI, independently predicted longer OS, and needs to be further explored.
Sections du résumé
BACKGROUND
BACKGROUND
To identify the predictive factors of recurrence and survival in an unselected population of Western patients who underwent multimodal percutaneous thermal ablation (PTA) for small Hepatocellular Carcinomas (HCCs).
METHODS
METHODS
January 2015-June 2019: data on multimodal PTA for <3 cm HCC were extracted from a prospective database. Local tumor progression (LTP), intrahepatic distant recurrence (IDR), time-to-LTP, time-to-IDR, recurrence-free (RFS) and overall (OS) survival were evaluated.
RESULTS
RESULTS
238 patients underwent 317 PTA sessions to treat 412 HCCs. During follow-up (median: 27.1 months), 47.1% patients had IDR and 18.5% died. LTP occurred after 13.3% of PTA. Tumor size (OR = 1.108,
CONCLUSIONS
CONCLUSIONS
IDR was associated with tumor aggressiveness, suggesting a metastatic mechanism. Besides AFP association with LTP, IDR, RFS and OS, treatment-naïve patients had longer RFS, and multi-nodularity was associated with shorter RFS and OS. Steatotic HCC, identified on pre-treatment MRI, independently predicted longer OS, and needs to be further explored.
Identifiants
pubmed: 32013112
pii: cancers12020313
doi: 10.3390/cancers12020313
pmc: PMC7072144
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Am Coll Surg. 2013 Dec;217(6):1054-62
pubmed: 24246620
Radiology. 2005 Aug;236(2):666-70
pubmed: 15995000
Radiology. 2009 Jan;250(1):95-102
pubmed: 19092092
J Hepatol. 2003 Feb;38(2):200-7
pubmed: 12547409
Hepatology. 2020 Jan;71(1):164-182
pubmed: 31206197
Biometrics. 2001 Mar;57(1):120-5
pubmed: 11252586
J Hepatol. 2019 Sep;71(3):616-630
pubmed: 31195064
J Hepatol. 2019 May;70(5):866-873
pubmed: 30615906
Radiology. 2014 Mar;270(3):900-9
pubmed: 24475823
Eur J Radiol. 2015 Jun;84(6):1036-43
pubmed: 25818729
Radiology. 2008 Sep;248(3):1056-66
pubmed: 18632532
J Gastroenterol. 2008;43(1):71-8
pubmed: 18297439
Eur J Radiol. 2006 Sep;59(3):432-41
pubmed: 16690240
J Hepatol. 2013 Jul;59(1):89-97
pubmed: 23523578
J Hepatol. 2014 Oct;61(4):840-9
pubmed: 24859455
J Hepatol. 2013 Jan;58(1):89-97
pubmed: 23023009
Hepatology. 2008 Jan;47(1):82-9
pubmed: 18008357
Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578
pubmed: 22158026
J Hepatol. 2017 Jan;66(1):67-74
pubmed: 27422750
J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S189-91
pubmed: 19559998
JAMA Oncol. 2019 Sep 27;:
pubmed: 31560378
Eur Radiol. 2007 Mar;17(3):684-92
pubmed: 17093964
J Vasc Interv Radiol. 2012 May;23(5):627-34
pubmed: 22387030
Eur J Radiol. 2011 Aug;79(2):e80-4
pubmed: 21514757
Histopathology. 2016 Dec;69(6):971-984
pubmed: 27380543
Am J Epidemiol. 2009 Jan 1;169(1):113-21
pubmed: 18990716
Radiology. 2015 Jun;275(3):908-19
pubmed: 25688888
J Vasc Interv Radiol. 2014 Nov;25(11):1691-705.e4
pubmed: 25442132
Hepatology. 2009 Nov;50(5):1475-83
pubmed: 19731239
J Hepatol. 2018 Apr;68(4):783-797
pubmed: 29031662
Am J Gastroenterol. 2009 Nov;104(11):2747-53
pubmed: 19603009
Int J Hyperthermia. 2018 Dec;35(1):90-96
pubmed: 29923441
Hepatology. 2006 May;43(5):1101-8
pubmed: 16628706
Int J Hyperthermia. 2015;31(7):749-57
pubmed: 26365503
Am J Surg Pathol. 2010 Nov;34(11):1630-6
pubmed: 20975341
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
AJR Am J Roentgenol. 2005 Oct;185(4):890-3
pubmed: 16177406
Radiology. 2016 Jul;280(1):300-12
pubmed: 26824711
Hepatology. 2011 Jan;53(1):136-47
pubmed: 20967759
J Hepatol. 2000 Aug;33(2):282-9
pubmed: 10952246
Cancer. 2005 Mar 15;103(6):1201-9
pubmed: 15690326
Oncology. 2007;72 Suppl 1:72-5
pubmed: 18087185